Using EEG visuospatial deficits to estimate clinical endpoints of dementia
Add us to your clinic today!
Reduce inconclusive test results with efficient dementia screening
Vistim Labs’ high-resolution biomarkers correlate with traditional PET/CSF & cognitive endpoints
Would you like to publish together as research partners?
Vision
We see a new standard of care where patients, clinicians, and researchers can quickly and easily perform dementia screening in-office, enabling opportunities to intervene to save individuals, families, and communities.
Mission
To increase patient access to care and to empower clinical decision making ability with our dementia screening tools. Our AI estimates clinical endpoints of neurodegeneration by identifying visuospatial & cognitive deficits from stimulated EEG patterns that indicate specific levels of amyloid and tau protein accumulation as well as cognitive impairment.
Learn more about our science
Relevant Press & Publications
VISTIM LABS UNVEILS NOVEL BIOMARKERS AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2023
VISTIM LABS WINS 1ST PLACE & $10K GRANT AT INVENTURES HEALTH COMPETITION
VISTIM LABS PUBLISHES NEW FINDINGS IN ALZHEIMER’S RESEARCH AND THERAPY JOURNAL
VISTIM LABS WINS 1ST PLACE & $10K GRANT AT STARTUP SAN DIEGO COMPETITION
VISTIM LABS 1 OF 11 INVITED TO EXCLUSIVE ACCELERATOR, PHARMSTARS
